Tepotinib (Tuodekang) efficacy evaluation and summary of clinical research data

Tepotinib (trade name Tepmetko) is an oral, highly selective METtyrosine kinase inhibitor, mainly used to treat patients with METNSCLC) with n>exon14 skipping mutations (METex14). The drug was approved in Japan in 2020 and was subsequently approved in the United States and Europe. Its efficacy and safety have been verified through multiple clinical studies, especially its outstanding performance in the VISION study.

1. VISIONStudy: Key clinical data of tepotinib

VISION is a multicenter, open-label, single-arm Phase II clinical trial designed to evaluate the efficacy and safety of tepotinib in patients with advanced NSCLC with METex14 skipping mutations. The study results showed that tepotinib had significant anti-tumor activity in these patients.

According to a preliminary analysis published in the New England Journal of Medicine in 2020, tepotinib demonstrated an objective response rate (ORRORRof 99 patients) of 46.5% pan>), the median progression-free survival (PFS) was 8.5 months, and the median overall survival (OS) was 19.5 months. These results demonstrate that tepotinib has durable clinical activity in patients with METex14-mutated NSCLC.

Further analysis showed that tepotinib showed good efficacy in different subgroups of patients, including elderly patients aged ≥80 years old, patients who had previously received chemotherapy or immune checkpoint inhibitor treatment, and patients with brain metastases. Especially in patients with brain metastases, tepotinib showed a good intracerebral control rate, and 13 out of 13 evaluable patients achieved control of brain metastases.

2. Long-term efficacy and survival benefit

In a study published in JAMA Oncology in 2023, the long-term efficacy of tepotinib in patients with METex14mutated NSCLC was evaluated. The study results showed that tepotinib had durable antitumor activity and was well tolerated in these patients. Median PFS was 9.1 months, and median OS was 20.1 months. In addition, tepotinib has a good safety profile, with common adverse reactions including edema, nausea, diarrhea, and muscle pain.

Additionally, a UK-based modeling study estimated the long-term survival benefit of tepotinib compared with current standard treatments, such as chemotherapy or immunotherapy. The results showed that tepotinib extended the median survival by 15.4 months in untreated patients and by 12.8 months in previously treated patients. These results further support the efficacy advantage of tepotinib in patients with METex14mutated NSCLC.

3. Safety and tolerability of tepotinib

The safety of tepotinib was fully evaluated in the VISION study. Common adverse reactions include edema (54.1%), nausea (20.0%), diarrhea ( 19.6%), myalgia (17.6%), and hypoalbuminemia (14.5%). Most of these adverse reactions are mild or moderate and can be alleviated by symptomatic treatment. The incidence of serious adverse reactions was low, and most patients tolerated treatment with the drug.

It should be noted that tepotinib may cause interstitial lung disease (ILD) and liver function damage, so the patient's lung function and liver function need to be closely monitored during treatment. In addition, tepotinib may have teratogenic effects on the fetus and is contraindicated in pregnant women. Women of childbearing age should take effective contraceptive measures.

4. Clinical Application and Future Prospects

Tepotinib, as a targeted therapy, isMETex14Mutated advanced NSCLC offers new treatment options for patients. Its significant efficacy and good safety profile make it one of the first-line treatment options for these patients. However, further studies are still needed to evaluate the combined therapeutic effect of tepotinib with other targeted drugs (such as capmatinib, erlotinib) or immune checkpoint inhibitors, in order to improve the efficacy of treatment and patient survival benefit.

In short, tepotinib has shown significant efficacy and good safety in patients with METex14 mutationsNSCLC and has become an important treatment option for these patients. With the deepening of research, tepotinib has broad clinical application prospects and deserves further attention.

Reference link:https://www.drugs.com